Cytomegalovirus (CMV) infection remains one of the most significant complications in transplant medicine, particularly in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). For compounding pharmacies in France, the growing demand for advanced antiviral solutions presents a timely opportunity—especially with the availability of Letermovir, a next-generation antiviral agent that is reshaping CMV prophylaxis globally.

MedicaPharma now supplies GMP-grade Letermovir API to French pharmacies and pharmaceutical manufacturers looking to expand their offerings to transplant centres, immunocompromised populations, and clinical specialists. With its novel mechanism of action and integration into international transplant protocols, Letermovir is a strategically important molecule for forward-looking compounders operating in this complex therapeutic area.

Download GMP-Certified API Product List

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations. Click here to download our complete API product list.

“Medicapharma’s products and services are exclusively available to licensed companies and professionals. We do not sell to individuals or private consumers.”

What Is Letermovir?

Letermovir is a selective antiviral developed specifically for the prevention of CMV infection in adult HSCT recipients. Unlike traditional antivirals such as ganciclovir or valganciclovir, which target viral DNA polymerase, Letermovir acts on the CMV terminase complex—a vital component in viral DNA processing and packaging. This targeted mechanism inhibits viral replication without affecting host cellular enzymes, offering greater specificity and improved tolerability.

Approved by both the European Medicines Agency (EMA) and the U.S. FDA, Letermovir has become a standard prophylactic agent in many transplant protocols worldwide. Its relevance continues to grow as more transplant centres integrate it into first-line prevention strategies, including those in France’s expanding network of university hospitals and cancer institutes.

The Role of Letermovir in the French Healthcare Landscape

France has one of the most advanced transplant care systems in Europe, with numerous public and private centres offering allogeneic HSCT. CMV infection remains a leading cause of post-transplant morbidity, often requiring intensive monitoring and treatment.
While traditional antivirals remain effective, their side effect profiles—including bone marrow suppression and renal toxicity—can limit their use in vulnerable patients.

Letermovir presents a compelling alternative. Its improved safety profile allows for early, sustained prophylaxis without negatively impacting hematopoiesis or renal function. For French compounding pharmacies, Letermovir opens the door to supporting specialised transplant units with a high-value molecule backed by strong clinical evidence and broad regulatory acceptance across the EU.

Clinical Advantages of Letermovir

Letermovir’s clinical benefits are well established in peer-reviewed trials. It significantly reduces the incidence of CMV reactivation in seropositive HSCT recipients and enables more effective CMV management without the use of hematotoxic agents. Its pharmacokinetic properties also support flexible administration, with both oral and intravenous formulations available.

For compounding pharmacies, this offers versatility. Letermovir can be formulated in various dosage forms to accommodate patient-specific needs, such as for paediatric patients, those unable to take oral medication, or cases requiring dose adjustments. This adaptability makes it a valuable addition to hospital-based pharmacies and specialist compounding facilities serving transplant populations.

MedicaPharma: GMP-Grade Letermovir for the French Market

MedicaPharma offers Letermovir API manufactured under GMP conditions and authorised by the Dutch Ministry of Health. All products are supplied with complete technical and regulatory documentation, ensuring full traceability and compliance with EMA and ANSM (Agence nationale de sécurité du médicament et des produits de santé) standards.

Each batch includes:

• Certificate of Analysis (CoA)
• Material Safety Data Sheet (MSDS)
• Full batch traceability documentation
• Regulatory support for French and EU markets

Our team works with pharmaceutical partners across France to ensure timely delivery, clear documentation, and responsive service—enabling consistent, compliant access to Letermovir for both commercial production and specialised compounding.

Supporting France’s Leadership in Transplant Medicine

France is a leader in European transplant care, with highly specialised centres in cities such as Paris, Lyon, Toulouse, and Marseille. These institutions are adopting more personalised approaches to infection prevention in immunocompromised patients, including off-label compounding where supported by clinical evidence.

Letermovir’s novel mechanism and tolerability make it an ideal candidate for integration into these evolving protocols. Compounding pharmacies that offer Letermovir-based formulations can support hospital units by improving access to timely, individualised prophylaxis strategies, especially for patients with unique clinical profiles or intolerance to standard treatments.

Request Letermovir from MedicaPharma

The demand for advanced CMV prophylaxis in France is growing. Hospitals and transplant centres are increasingly turning to newer agents like Letermovir that align with modern standards of care. For compounding pharmacies, this is a key opportunity to supply a molecule with strong clinical backing and increasing clinical uptake across Europe.

MedicaPharma offers EU-GMP-certified Letermovir with complete documentation and flexible supply options. Whether you are supporting a university hospital, a private clinic, or a research-focused CDMO, we deliver the product quality and regulatory readiness you need to integrate Letermovir into your operations.

Request a quote today to learn more about our Letermovir API and how MedicaPharma can support your work in CMV prevention for the French healthcare market.